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Abstract Toll-like receptors (TLRs) are considered now as
crucial sensors of innate immunity. Their role in the
recognition of pathogens and the initiation of adaptive
immune responses against them is well known. However, in
last years TLRs have been identified on several tumor cells,
including human malignancies. Their expression in cancer
was found to be twofold: either promoting or inhibiting tumor
progression. It was also demonstrated that several TLRs
agonists, either natural or synthetic ones, may have beneficial
effect on tumor-mediated disease, leading to potentiation of
immune response to tumor-associated antigens. TLR-agonist
linked tumor immunotherapy is still in nascent state, but
growing rapidly, also in the area of common human
malignancies. To date, the most promising and the most
frequently studied interaction in tumor immunotherapy trials
seems to be TLR9 and its synthetic agonists.
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Toll-like receptors (TLRs) a group out of evolutionally
conserved family of pattern recognition receptors (PRRs)
have gained great interest in a large community of life
science researchers [1, 2]. TLRs recognize mainly products
of microbial origin, known as pathogen-associated molec-
ular patterns (PAMPs). The latter include a large variety of
various organic compounds such as lipopolysaccharides
(LPS) from Gram-negative bacteria, viral single and
double-stranded RNAs, various sugars, unmethylated CpG
oligonucleotides (CpG-ODN) and others. To date, 10
members of TLR family, (designed from TLR1 to TLR10)
have been identified in humans, reflecting the reactivity
with particular PAMPs [3]. In functional terms, TLRs,
following dimerization, signal through the cytoplasmic
Toll/interleukin-1 receptor domain (TIR). Several other
adaptor molecules and enzymes participate in the signaling,
including MD-2, MyD88, IL-1 receptor-associate kinases
(IRAK-4 and IRAK-1), TNF-receptor associated factor
(TRAF), mitogen-activated protein kinase (MAPK) and
others. Out of them MyD88 (myeloid differentiation
primary-response protein 88) adaptor protein seems to be
the most important, because all TLRs with the exception of
TLR3, require MyD88 pathway for the initiation of
synthesis of proinflammatory cytokines. Besides, MyD88
possess N-terminal death domain enabling it to interact
with IL-1 receptor-associated kinase (IRAK). TLR3 uses
MyD88-independent/TRIF-dependent pathway to induce
IRF3, being critical for the induction of antiviral immunity.
The net effect of signaling is the activation of transcription
factors such as NF-κB and AP-1. Their entrance to the cell
nucleus result in the transcription of several genes encoding
a variety of biologically relevant macromolecules such as
proinflammatory cytokines, chemokines, growth factors etc.
Simplified biochemical events in cell interior happening after
various TLRs signaling are shown in Fig. 1.P r e c i s e
biochemical sequence of incidents accompanying TLR
Fig. 1 Signal transduction pathways of Toll-like receptors. TLRs are
both, extracellular and intracellular. Individual TLRs have various
pathways of signal transduction, either MyD88
+ or MyD88
− (TLR3
only and partly TLR1/TLR2). Binding of ligand by TLR results in the
activation of cascade of kinases, leading to the entry of transcription
factors, such as NF-κB, AP1 and IRF to cell nucleus
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TLRs are outside the scope of the present review and may be
found elsewhere [4]. The opinion is generally held that TLR
signaling constitutes a key component of the innate immune
response to microbial infection [5, 6].
TLRs are expressed in both, lymphoid and non-lymphoid
tissues, but expression in the former predominates. Practi-
cally all cells of the immune system express TLRs, but the
pattern of expression varies with the cell type. Stimuli able to
induce activation of TLRs are heterogenous and include,
apart from microbial compounds, other agents such as injury
induced by excessive heat [7], various chemicals, ionizing
radiation etc. There is an evidence that in addition to their
function as sensors of foreign PAMPs, TLRs can also
mediate responses to endogenous stimuli. The latter com-
prise various factors such as heat shock proteins (HSP),
necrotic debris, fibrinogen, degraded fibronectin fragments
[8] and other cell and/or body constituents [9].
Apart from positive stimuli of TLR system, both
exogenous and endogenous ones, the system is also under
negative regulation, preventing excessive inflammatory
responses. There are several agents involved, but good
example of them is single immunoglobulin IL-1-related
protein (SIGIRR) expressed on epithelial cells of liver,
kidney, intestine but also on dendritic cells [10]. SIGIRR is
able to inhibit MyD88-related pathway and NF-κB activa-
tion. Several other negative regulators have been described,
including extracellular ones such as soluble decoy TLRs,
transmembrane (SIGIRR) and intracellular (Toll-interacting
protein—Tollip). More data about negative regulation of
TLRs are available in recently published excellent review
article of Lang and Mansell [11].
TLR Expression on Tumor Cells and their Putative
Function
There is an accumulating and steadily growing evidence
that cells of several human malignancies express single or
more commonly multiple TLRs. Significance of this
phenomenon is far from clear, There are, however several
lines of evidence suggesting biological impact of TLRs
expression on tumor cell growth and survival. For example,
Hassan et al. [12] have shown that cells of human
neuroblastoma express intracellular form of TLR4. More-
over, these cells show expression of factors required for
LPS response such as CD14, MyD88 and MD2, what
suggests, that TLR4 expression is functional.
He et al. [13] demonstrated negative function of TLR4
expression in human lung cancer cell lines. Ligation of LPS
agonist by the above mentioned cells resulted in the
production of immunosuppressive cytokines such as TGFβ
and in the resistance to TNFα or TRAIL-induced apoptosis.
There is also evidence that bacteria present in the tumor
microenvironment are able to promote tumor growth via
TLR signaling. Huang et al. [14] have shown that Listeria
monocytogenes when present in the microenvironment of
large, but not small tumors, accelerate tumor growth via
TLR2 signaling. Apparently the same or similar mechanism
operates in gastric carcinoma patients due to the interaction
of their cells expressing TLRs with Helicobacter pylori
bacteria, in contrast to normal situation, when interactions
between commensal bacteria and gastro-intestinal mucosa
through Toll-like receptors maintain homeostasis [15, 41].
Similarly, human myeloma cells express several TLRs,
such as TLR1, 7 and 9. Their activation by bacterial ligands
from infecting bacteria promote tumor growth and the
escape from conventional therapies [16].
Kelly et al. [42] have shown that MyD88
+ ovarian
cancer cell line cells differ from those MyD88
−. LPS
signaling of MyD88
+ cancer cells resulted, apart from
production of proinflammatory cytokines, in the induction
of tumor growth. Moreover, MyD88 expression was
associated with anti-cancer drug, paclitaxel resistance and
expression of antiapoptotic proteins. It was not the case,
when MyD88
− cancer cells were tested. This suggests, that
MyD88 adaptor protein expression in cancer cells is of
crucial importance in tumor biology.
Kundu et al. [17] have shown that immortalized prostate
epithelial cells, expressing both TLR4 and TLR9, exhibit
enhanced proliferation when cultured in the presence of
lipopolysaccharide (LPS) and CpG DNA, their respective
ligands. These stimulated cells were shown to be less
susceptible to TNF-alpha induced apoptosis and to cell
death due to high concentrations of LPS. Other authors
such as Ilvesaro et al. [18] provided evidence that TLR9
agonistic unmethylated CpG oligonucleotides (CpG-ODN)
promote matrix metalloproteinase-13 (MMP-13) activity
resulting in enhanced migration of human prostate cancer
cells expressing TLR9. Both LPS and CpG-ODN are well-
known surrogate molecules for pathogens residing in
genitourinary system such as E. coli, and some DNA
viruses (HPV for example). Overall, these data show that
pathogens frequently encountered in this milieu may
enhance malignant transformation and boost cancer cell
spreading.
Moreover, it has been found that not only natural, but also
synthetic CpG-ODN may function as vaccine adjuvants for
infectious diseases as well as for cancer [19].
The role of TLRs expressed on tumor cells in the evasion
of immune surveillance was elegantly demonstrated in
animal experiments [20]. These authors have shown on
several mouse tumor and tumor cell line systems that TLR4
activation by LPS enhances immune suppression in vitro.
This inhibitory effect could be reversed by both, TLR4 short
interfering RNA (siRNA) and TLR4 peptide. TLR4 stimu-
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several proinflammatory cytokines such as IL-6 and IL-12.
Both, nitric oxide and IL-6 were shown to inhibit T cell
proliferation and NK cell activity. Blockage of tumor TLR4
signaling by siRNA or TLR4 peptide led to prolongation of
survival of tumor-bearing mice. These results show unequiv-
ocally that TLRs stimulation may lead to tumor progression
and there are now means able to specifically reverse this
unwanted effect.
On the other hand, Salaun et al. [21] demonstrated, that
TLR3 on human breast cancer cells may drive these cells to
apoptosis. Synthetic dsRNA, TLR3 agonist, induced apo-
ptosis of 3 out 4 human breast cancer cell lines. Apoptosis
was both, TLR3 and TRIF (adaptor molecule) dependent.
TLR3 expressed by tumor cells was also able to drive cells
into apoptosis, when stimulated by type I interferon. These
data are important, because they provide evidence that
cancerous cells may be triggered to death by endogenously
derived factor. Functional TLRs expression has been
demonstrated on cells of several human cancers, including,
for example, squamous cell lung carcinoma cells expressing
TLR9 [22].
We were able to show expression of TLR2, TLR3 and
TLR4 on tumor cells of laryngeal carcinoma, using frozen
tissue sections, appropriate antibodies, respective blocking
peptides to assure specificity, and immunohistochemistry
[23]. This tumor, in overwhelming majority originates from
squamous, often keratinizing epithelium. Keratinocytes
were shown to express functional Toll-like receptors [24].
It was also of interest from results of our study, that TLRs
were found to be co-expressed with HLA-DR antigens,
what might suggest the role of TLRs in putative tumor
antigen presentation. Our recent data from experiments
done on tissue culture cell lines of HNSCC hint for reverse
biological function of TLR4 and TLR9. TLR4 expression
seemed to support tumor progression, while TLR9 sensi-
tized tumor cells to drug-mediated apoptosis [unpublished].
TLR Agonists as Possible Agents in Tumor
Immunotherapy
The overall data presented above suggest that TLRs action in
malignant process may be twofold: stimulation may promote
tumor progression or it may have anti-tumor effect [27]. The
latter action became recently the area of intensive study. It
has been noticed by several investigators that some agonists
of TLRs may induce strong anti-tumor activity. The best
known such agent is imiquimod, a TLR7 agonist, used in the
treatment of basal and squamous cell carcinoma [25, 26].
Okamoto and Sato [28] have isolated organic compound
OK-432 and later its component OK-PSA from Streptococcus
pyogenes strain. They have shown that these agents induce
strong anti-cancer immunity via TL4/MD2 signaling in a
mouse model. Moreover, they also reported that OK-432
based immunotherapy is effective in the treatment of patients
with oral squamous cell carcinoma [29].
In the case of human melanoma, the malignancy subjected
to the most extensive research programs, it was found, that
human melanoma cells express functional TLR3 protein.
TLR3 agonistscan directly prevent cell proliferation and even
induce cell death, when such treatment is combined with
either type I interferon or inhibitors of protein synthesis [30].
In chronic lymphocytic leukemia tumor cells show
strong expression of a large variety of TLRs, especially
TLR7 and TLR9. Activation of the former by the respective
agonists such as imidazoquinolines, TLR7 agonists may
make tumor cells more sensitive to killing by both, cells of
the immune system and chemotherapeutic agents. This is
now a subject of phase I trials in several centers [31].
Schmidt et al. [32] have recently shown that also
intratumoral injection of TLR2/6 agonist (macrophage
activating lipopeptide-2, MALP-2) significantly prolonged
survival of patients with pancreatic carcinoma, from 9 to
17 months. These findings are of importance, because they
show interactions between TLRs and their agonists are
Table 1 Examples of clinical trials using TLR agonists in cancer patients
Agent agonist Cancer Details Results Ref.
Imiquimod (TLR7
agonist)
Basal and squamous
cell carcinoma
Topical application of 5% cream
five times weekly for 6 weeks
Residual tumor in 7.5% of
patients
Tillman and Carroll
[26]
TLR 3 agonist Melanoma Combined with IFN type I or
with protein synthesis inhibition
Inhibition of cell proliferation
induction of cell death
Salaun et al. [30]
PF3512676 (TLR9
agonist)
Metastatic
melanoma
6 mg S.C./24 weeks Stimulation of innate response Pashenkov et al. [33]
Imidazoquinoline
528690 (TLR7)
Chronic
lymphocytic B
leukemia
TLR7 tolerization by agonist Increased sensitivity of tumor
cells to cytotoxic chemotherapeutics
Spaner and Masellis
[31]
TLR2/6 MALP-2
(synthetic)
Pancreatic
carcinoma
Intratumoral together with
gemcitabine
Prolongation of life for 8 months
in average
Schmidt et al. [32]
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human tumor immunotherapy using TLR agonists are
shown in Table 1. Current situation in this field, prospects
and challenges have been recently discussed by Rezaei [34]
and Romagne [35].
The question remains, what is the mechanism of
beneficial effect of TLRs activation by agonists in
malignant disease. Several lines of evidence indicate, that
tumor cells exert inhibitory effect on various aspects of the
immune system. It is manifested by the inhibition of
maturation of dendritic cells [36], by the effect of secreted
immunosuppressive cytokines such as IL-10 and TGFβ,a s
shown in our previous studies [37] and other.
It appears that TLR-mediated signaling induced by
agonists enhances the maturation of dendritic cells. It
results in their migration to the regional lymph nodes,
presentation of tumor antigens to T cells, production of
cytokines such as IL-12 and IL-18, what all together
redirects immune response to Th-1 type, beneficial for
cancer patients in most clinical situations [28].
It remains of interest, how TLR signaling in malignant
disease may be linked to the effects of conventional anti-cancer
treatment such chemotherapy and radiotherapy. The data
provided by French group, of Apetoh et al. [38]s h e dn e w
light on this fascinating issue. These authors have found that
dying tumor cells secrete peculiar alarmin protein, called
high-mobility group box 1 (HMGB1) able to react with TLR4
on dendritic cells. This provides DC an impetus for efficient
processing and cross-presentation of antigens from degraded
tumor cells. Moreover, in the case of TLR4 polymorphism,
manifested by TLR4 loss-of-function allele this DC function
was lost, what resulted in early tumor relapse, at least in breast
cancer patients [39]. It remains to find whether other cancer
cells secrete such alarmin protein as breast cancer ones.
However, one should be aware of the fact, that not all
tumor cells express TLRs, and not all TLR agonists as well
as not all types of cell signaling mediated by TLRs induce
“good” Th1-type response. Besides, TLR polymorphisms on
tumor cells may produce unwanted effects during attempts of
artificial TLR signaling by applied ligands [40]. Thus, the
field of TLR-mediated tumor immunotherapy and links of
TLRs signaling with conventional anti-tumor therapies still
awaits intensive research efforts.
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